Benefit of folic acid supplementation in parkinsonian patients treated with levodopa [5]

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 4, 2003, Pages 549-

  Muller T ^a   Woitalla, D ^a   Kuhn, W ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; LEVODOPA;

BASAL GANGLION; BRAIN ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; DISEASE PREDISPOSITION; ENERGY METABOLISM; HUMAN; LETTER; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSONISM; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

EID: 0037379897     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.4.549     Document Type: Letter

References (5)

1. Reynolds EH. Benefits and risks of folic acid to the nervous system. J Neurol Neurosurg Psychiatry 2002;72:567-71.
2. Müller T, Woitalla D, Fowler B, et al. 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neurol Transm 2002;109:175-9.
3. Müller T, Woitalla D, Hauptmann B, et al. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001;308:54-6.
4. Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-9.
5. Schlussel E, Preibisch G, Putter S, et al. Homocysteine-induced oxidative damage: mechanisms and possible roles in neurodegenerative and atherogenic processes. Z Naturforsch [[C]] 1995;50:699-707.